Effect of gamma globulin pulse therapy on patients with severe community-acquired pneumonia and on serum immune proteins and lymphocyte subsets
-
摘要:
目的 探究丙种球蛋白冲击治疗重症社区获得性肺炎(severe community acquired pneumonia, SCAP)的疗效,对患者临床症状的改善以及血清免疫蛋白和淋巴细胞亚群水平的影响。 方法 选取2017年1月—2020年1月于金华市中心医院接受治疗的100例SCAP患者,采用随机数字表法分为观察组和对照组,各50例。对照组患者予以对症干预治疗。观察组加用丙种球蛋白。治疗7 d后比较2组患者疗效。治疗前后记录患者氧分压(PaO2)、二氧化碳分压(PaCO2)、血氧饱和度(SpO2)、血清超敏C反应蛋白(hsCRP)、降钙素原(PCT)水平以及急性生理与慢性健康状况(APACHEⅡ)评分,测定血清免疫球蛋白G/A/M(IgG/A/M)、补体以及淋巴细胞亚群比例。 结果 观察组总有效率(94.00%)高于对照组(80.00%, χ2=4.332,P=0.037);治疗后2组患者PaO2、SpO2均较同组治疗前升高,且观察组均高于对照组,PaCO2、hsCRP、PCT水平以及APACHEⅡ评分均较治疗前降低,且观察组均低于对照组(均P < 0.05);治疗后观察组IgG水平较同组治疗前升高,且高于对照组(P < 0.05);治疗后观察组CD4+、CD4+/CD8+均较治疗前升高,且观察组均高于对照组,CD8+较治疗前降低,且观察组低于对照组(均P < 0.05)。 结论 丙种球蛋白冲击治疗SCAP可改善患者免疫系统功能和淋巴细胞亚群比例,疗效较好。 Abstract:Objective To explore the efficacy of gamma globulin pulse therapy in treating severe community-acquired pneumonia (SCAP), improving clinical symptoms and influencing the levels of serum immune protein and lymphocyte subsets. Methods A total of 100 patients with SCAP who were treated in Jinhua Central Hospital of Zhejiang Province from January 2017 to January 2020 were randomly divided into the observation group (50 cases) and control group (50 cases) by using the random number table. The control group was given symptomatic intervention, whilst the observation group received intravenous infusion of gamma globulin on the basis of the control group. After 7 days of treatment, the efficacy of the two groups was compared. Before and after treatment, the patients' partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2), percutaneous oxygen saturation (SpO2), serum high-sensitivity C-reactive protein (hsCRP), procalcitonin (PCT) levels, and acute physiology and chronic health evaluation (APACHE Ⅱ) score were recorded. The serum immunoglobulin G/A/M (IgG/A/M), complement levels and lymphocyte subset ratio were measured. Results The total effective rate in the observation group (94.00%) was higher than that in the control group (80.00%, χ2=4.332, P=0.037). Moreover, the PaO2 and SpO2 of both groups after treatment were higher than those before treatment, and the values were higher in the observation group compared with the control group. The levels of PaCO2, hsCRP, PCT and APACHE Ⅱ score were lower after treatment than before treatment, and they were lower in the observation group than in the control group (all P < 0.05). The IgG level of the observation group after treatment was higher than that before treatment, and the observation group had higher IgG level than the control group (P < 0.05). Moreover, the concentrations of CD4+ and CD4+/CD8+ in the observation group were higher after treatment than before treatment, and the observation group had higher concentrations than the control group. Meanwhile, the concentration of CD8+ was lower after treatment than before treatment, and the observation group had lower concentration than the control group (all P < 0.05). Conclusion Gamma globulin pulse therapy can improve the immune system function and lymphocyte subset ratio of patients with SCAP. -
表 1 2组SCAP患者一般资料比较
组别 例数 性别[例(%)] 年龄(x±s, 岁) CPIS评分(x±s, 分) APACHEⅡ评分(x±s,分) 合并2型糖尿病[例(%)] 合并高血压[例(%)] 合并冠心病[例(%)] 病原学阳性[例(%)] 男性 女性 肺炎链球菌 肺炎克雷伯菌 金黄色葡萄球菌 大肠埃希菌 对照组 50 36(72.00) 14(28.00) 63.18±10.27 10.18±0.69 30.86±4.51 19(38.00) 18(36.00) 14(28.00) 11(22.00) 3(6.00) 6(12.00) 1(2.00) 观察组 50 37(74.00) 13(26.00) 62.37±9.82 10.32±0.75 31.27±4.72 18(36.00) 21(42.00) 13(26.00) 12(24.00) 4(8.00) 7(14.00) 1(2.00) 统计量 0.051a 0.403b 0.971b 0.444b 0.043a 0.378a 0.051a 0.364a P值 0.822 0.688 0.334 0.658 0.836 0.539 0.822 0.546 注:a为χ2值,b为t值。 表 2 2组SCAP患者临床疗效比较[例(%)]
组别 例数 显效 有效 无效 总有效 对照组 50 19(38.00) 21(42.00) 10(20.00) 40(80.00) 观察组 50 23(46.00) 24(48.00) 3(6.00) 47(94.00) 注:2组总有效率比较,χ2=4.332,P=0.037。 表 3 2组SCAP患者治疗前后临床症状变化(x±s)
组别 例数 PaO2(mm Hg) PaCO2(mm Hg) SpO2(%) 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 对照组 50 51.83±5.61 79.32±6.49a 54.29±8.16 44.62±6.93a 72.13±3.92 90.05±6.18a 观察组 50 51.64±5.53 83.84±7.25a 53.94±8.04 41.19±5.87a 71.81±3.76 94.31±6.52a t值 0.171 3.285 0.216 2.686 0.417 3.274 P值 0.865 0.001 0.829 0.009 0.678 0.002 组别 例数 hsCRP(mg/L) PCT(μg/L) APACHEⅡ评分(分) 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 对照组 50 138.92±21.57 38.97±7.64a 1.35±0.41 0.83±0.17a 30.86±4.51 23.68±4.03a 观察组 50 139.37±22.36 21.53±5.12a 1.37±0.43 0.51±0.09a 31.27±4.72 20.94±3.85a t值 0.102 13.409 0.238 11.763 0.444 3.476 P值 0.919 < 0.001 0.812 < 0.001 0.658 0.001 注:与同组治疗前比较,aP < 0.05。1 mm Hg=0.133 kPa。 表 4 2组SCAP患者治疗前后免疫球蛋白水平比较(x±s, g/L)
组别 例数 IgG IgA IgM 补体C3 补体C4 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 对照组 50 5.12±1.06 5.24±1.18 1.06±0.25 1.12±0.29 0.83±0.12 0.89±0.19 0.92±0.17 0.96±0.19 0.59±0.11 0.62±0.14 观察组 50 5.09±1.02 8.93±1.64a 1.08±0.26 1.12±0.31 0.85±0.16 0.91±0.15 0.93±0.15 0.98±0.21 0.61±0.12 0.63±0.15 t值 0.144 12.914 0.392 < 0.001 0.707 0.584 0.312 0.499 0.869 0.345 P值 0.886 < 0.001 0.696 0.999 0.481 0.560 0.756 0.619 0.387 0.731 注:与同组治疗前比较,aP < 0.05。 表 5 2组SCAP患者治疗前后淋巴细胞亚群比较(x±s)
组别 例数 CD4+(%) CD8+(%) CD4+/CD8+ 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 对照组 50 21.53±7.92 23.61±10.18 20.26±6.18 18.14±5.37 1.06±0.43 1.30±0.57a 观察组 50 22.04±8.03 28.57±11.24a 20.31±6.34 16.26±3.82a 1.09±0.46 1.76±0.63a t值 0.320 2.313 0.040 2.017 0.055 3.829 P值 0.750 0.023 0.968 0.046 0.956 < 0.001 注:与同组治疗前比较,aP < 0.05。 -
[1] LANKS C W, MUSANI A I, HSIA D W. Community-acquired pneumonia and hospital-acquired pneumonia[J]. Med Clin North Am, 2019, 103(3): 487-501. doi: 10.1016/j.mcna.2018.12.008 [2] TORRES A, CHALMERS J D, DELA C C, et al. Challenges in severe community-acquired pneumonia: A point-of-view review[J]. Intensive Care Med, 2019, 45(2): 159-171. doi: 10.1007/s00134-019-05519-y [3] 马文君, 贾换. 丙种球蛋白联合地塞米松治疗重症肺炎的效果[J]. 河南医学研究, 2020, 29(7): 1259-1260. doi: 10.3969/j.issn.1004-437X.2020.07.054 [4] YANG L, WU E Y, TARRANT T K. Immune gamma globulin therapeutic indications in immune deficiency and autoimmunity[J]. Curr Allergy Asthma Rep, 2016, 16(8): 55. doi: 10.1007/s11882-016-0632-7 [5] 中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核和呼吸杂志, 2016, 39(4): 253-279. doi: 10.3760/cma.j.issn.1001-0939.2016.04.005 [6] RIDER A C, FRAZEE B W. Community-acquired pneumonia[J]. Emerg Med Clin North Am, 2018, 36(4): 665-683. doi: 10.1016/j.emc.2018.07.001 [7] 张颜苹, 霍建民, 陈晓灿. 成人社区获得性肺炎病情评估的研究进展[J]. 临床肺科杂志, 2020, 25(1): 143-146. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFK202001035.htm [8] GARNACHO-MONTERO J, BARRERO-GARCIA I, GOMEZ-PRIETO M G, et al. Severe community-acquired pneumonia: Current management and future therapeutic alternatives[J]. Expert Rev Anti Infect Ther, 2018, 16(9): 667-677. doi: 10.1080/14787210.2018.1512403 [9] WUNDERINK R G. Guidelines to manage community-acquired pneumonia[J]. Clin Chest Med, 2018, 39(4): 723-731. doi: 10.1016/j.ccm.2018.07.006 [10] 李海. 糖皮质激素对重症社区获得性肺炎合并脓毒性休克患者的治疗效果分析[J]. 河南医学研究, 2018, 27(11): 2014-2015. doi: 10.3969/j.issn.1004-437X.2018.11.048 [11] 李洁, 陈滔. 人血丙种球蛋白对儿童难治性肺炎支原体肺炎的作用效果[J]. 中国妇幼保健, 2020, 35(7): 1267-1269. https://www.cnki.com.cn/Article/CJFDTOTAL-ZFYB202007034.htm [12] RAMUS B, BENBRAHIM O, CHERIN P. Use of intravenous and subcutaneous human immunoglobulins[J]. Soins, 2019, 64(833): 13-18. doi: 10.1016/j.soin.2019.01.016 [13] 褚祝飞, 魏利锋, 周超群. 丙种球蛋白对支原体肺炎合并肺不张患儿免疫功能、炎性指标的影响[J]. 现代实用医学, 2020, 32(3): 360-362. doi: 10.3969/j.issn.1671-0800.2020.03.037 [14] LEONI D, RELLO J. Severe community-acquired pneumonia: Optimal management[J]. Curr Opin Infect Dis, 2017, 30(2): 240-247. doi: 10.1097/QCO.0000000000000349 [15] 黄宏佳, 罗海清, 郑文枝, 等. C反应蛋白在社区获得性肺炎严重程度和预后评估中的作用[J]. 实用心脑肺血管病杂志, 2018, 26(2): 99-101. https://www.cnki.com.cn/Article/CJFDTOTAL-SYXL2018S2044.htm [16] 谢君杰, 易汛, 徐昉. 临床肺部感染评分和降钙素原对评估老年重症社区获得性肺炎患者病情和预后的意义[J]. 中华实验和临床感染病杂志(电子版), 2018, 12(1): 61-64. doi: 10.3877/cma.j.issn.1674-1358.2018.01.012 [17] CATAUDELLA E, GIRAFFA C M, DIMARCA S, et al. Neutrophil-to-lymphocyte ratio: An emerging marker predicting prognosis in elderly adults with community-acquired pneumonia[J]. J Am Geriatr Soc, 2017, 65(8): 1796-1801. doi: 10.1111/jgs.14894 [18] 代岩. 丙种球蛋白对重症肺炎患者血清细胞因子及免疫功能的影响[J]. 中国临床医生杂志, 2018, 46(7): 772-774. doi: 10.3969/j.issn.2095-8552.2018.07.006 [19] GUELL E, MARTIN-FERNANDEZ M, DELATORRE M C, et al. Impact of lymphocyte and neutrophil counts on mortality risk in severe community-acquired pneumonia with or without septic shock[J]. J Clin Med, 2019, 8(5): 754. doi: 10.3390/jcm8050754
计量
- 文章访问数: 87
- HTML全文浏览量: 173
- PDF下载量: 9
- 被引次数: 0